Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.

Levin, Seth N; Ezuma, Chimere; Levine, Libby; Vargas, Wendy S; Farber, Rebecca S; De Jager, Philip L; Riley, Claire S

Levin, Seth N; Ezuma, Chimere; Levine, Libby; Vargas, Wendy S; Farber, Rebecca S; De Jager, Philip L; Riley, Claire S.

Afiliación

Levin SN; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
Ezuma C; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
Levine L; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
Vargas WS; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
Farber RS; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
De Jager PL; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.
Riley CS; Department of Neurology and Multiple Sclerosis Center, Columbia University Irving Medical Center, New York, NY, USA.

Mult Scler ; 26(14): 1964-1965, 2020 12.

Article en En | MEDLINE | ID: mdl-32552363

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Anticuerpos Monoclonales Humanizados; Humanos; Factores Inmunológicos; Esclerosis Múltiple/tratamiento farmacológico; Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico; Natalizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google